ArticleAlzheimer's research & therapy2022
The course of primary progressive aphasia diagnosis: a cross-sectional study.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03687112 (National Bank Alzheimer), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
National Bank Alzheimer
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- FDG-PET in the diagnosis of primary progressive aphasia: a systematic review.Annals of nuclear medicine · 2024Pooled it
- Speech-based digital biomarkers for early etiological stratification of Alzheimer's disease and frontotemporal degeneration: a biomarker-confirmed prospective study.The journal of prevention of Alzheimer's disease · 2026Article
- Incidence of primary progressive aphasia in Salento, Italy: a population-based study.Alzheimer's research & therapy · 2026Article
- Empathy in primary progressive aphasia: Neural signatures and longitudinal trajectories.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Non-fluent agrammatic variant of primary progressive aphasia in a bilingual Mandarin/English speaker: a case report.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- From neighborhoods to brain health: an outreach model linking health literacy, cognitive care, research, and the arts, in San Francisco.Frontiers in public health · 2026Article
- Rethinking the diagnosis of primary progressive aphasia: current challenges and future directions.Frontiers in aging neuroscience · 2025Article
- Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.Current treatment options in neurology · 2025Review
- The Classification and Language Description of Patients with Primary Progressive Aphasia Using the Mini Linguistic State Examination Test.Geriatrics (Basel, Switzerland) · 2024Article
- Advancing Neuropsychological Rehabilitation in Primary Progressive Aphasia Based on Principles of Cognitive Neuroscience: A Scoping Review and Systematic Analysis of the Data.Brain sciences · 2024Article
- The Media Coverage of Bruce Willis Reveals Unfamiliarity With Frontotemporal Degeneration.Innovation in aging · 2023Article
- Logogenic Primary Progressive Aphasia or Alzheimer Disease: Contribution of Acoustic Markers in Early Differential Diagnosis.Life (Basel, Switzerland) · 2022Article
- Primary Progressive Aphasia: Use of Graphical Markers for an Early and Differential Diagnosis.Brain sciences · 2021Article
- Time to diagnosis in FTLD-associated syndromes in Latin America.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary progressive aphasia (PPA) diagnosis trajectory is debated, as several changes in diagnosis occur during PPA course, due to phenotype evolution from isolated language alterations to global cognitive impairment. The goal of the present study, based on a French cohort, was to describe the demographics and the evolution of subjects with (PPA) in comparison with Alzheimer's disease (AD) on a period of 7 years.
methodsWe conducted a repeated cross-sectional study. The study population comprised individuals with PPA and AD diagnosis (N=167,191) from 2010 to 2016 in the French National data Bank (BNA). Demographic variables, MMSE scores, diagnosis status at each visit and prescribed treatments were considered.
resultsFrom 2010 to 2016, 5186 patients were initially diagnosed with PPA, 162,005 with AD. Compared to AD subjects, significant differences were found concerning age (younger at first diagnosis for PPA), gender (more balanced in PPA), education level (higher in PPA) and MMSE score (higher of 1 point in PPA). Percentage of pending diagnosis, delay between first consultation and first diagnosis and the number of different diagnoses before the diagnosis of interest were significantly higher in PPA group compared to AD group. Pharmacological and non-pharmacological treatments were significatively more recommended following PPA than AD diagnosis.
conclusionThis study improves the knowledge of PPA epidemiology and has the potential to help adopting appropriate public health service policies. It supports the hypothesis that PPA is diagnosed later than AD. The PPA diagnosis increases the prescription of non-pharmacological treatments, especially speech and language therapy (SLT) that is the main treatment available and most effective when at the initial stage.
trial registrationClinicalTrials.gov identifier NCT03687112.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.